Earlydiagnostics Inc.
Agoura Hills, CA Doing business as Earlydx
- UEI
- SGJ1NZDE89G4
- CAGE
- 87YY4
- SAM.gov registration
- Active through
Company facts
- Self-certified in SAM.gov
- Entity structure
- Corporate Entity (Not Tax Exempt)
- NAICS codes registered in SAM.gov
- SAM.gov registration date
- Physical address
- 30601 Agoura Rd #250, Agoura Hills, CA 91301, USA
- Website
- earlydx.com
- Founded
- 2017
- Employees
- 1-10
- Estimated annual revenue
- $0-$1M
- Industry
-
- Health Care
- Health Care Equipment & Services
- Health Care Providers & Services
- Health Care Services
- SIC code
- 80 Health Services
- Profiles
Registration and certifications come from SAM.gov and the SBA; company details from public web sources. Updated .
Recent federal awards
| Award | Agency | Obligated | Awarded |
|---|---|---|---|
| Topic 428 - NCI sbir transition to phase II solicitation FY 2023 | National Cancer Institute | $1,994,911 | |
| Topic 428 "cloud-based liquid-biopsy platform for the cancer research data commons" | National Cancer Institute | $395,918 | |
| Methylscan for early detection of liver and lung cancer - project summary the long-term goal of this sbir phase II… | National Cancer Institute | $4,907,853 | |
| An accurate, non-invasive, and cost-effective methylome test for early cancer detection | National Cancer Institute | $351,646 |
About Earlydiagnostics Inc.
Earlydiagnostics Inc., doing business as Earlydx, is a for-profit corporate entity that provides accurate, affordable, and non-invasive methods for early cancer detection, including a blood test called CancerRadar. Through federal contracts, Earlydx has provided research and development aligned with developing a cloud-based liquid-biopsy platform for the Cancer Research Data Commons. This $395,918 firm fixed price contract was awarded by the National Institutes of Health National Cancer Institute under the Small Business Innovation Research program. The contract has a total small business set aside designation and no major subcontractors were identified.
Through federal grants, Earlydx has provided research and development of a blood-based methylation profiling test called MethylScan that can detect and locate multiple types of cancer early. A $4.9 million project grant was awarded by the National Institutes of Health National Cancer Institute to optimize the MethylScan assay and workflow and clinically validate it for early detection of liver and lung cancer. Earlydx also received a $351,646 project grant to develop an accurate, non-invasive, and cost-effective methylome test for early cancer detection.
Quick answers
What is Earlydiagnostics Inc.'s UEI?
Earlydiagnostics Inc.'s Unique Entity ID (UEI) in SAM.gov is SGJ1NZDE89G4.
What is Earlydiagnostics Inc.'s CAGE code?
Earlydiagnostics Inc.'s CAGE code is 87YY4.
What is Earlydiagnostics Inc.'s primary NAICS code?
Earlydiagnostics Inc.'s primary NAICS code is 541714 (Research and Development in Biotechnology (except Nanobiotechnology)).
Where is Earlydiagnostics Inc. located?
Earlydiagnostics Inc.'s physical address in SAM.gov is 30601 Agoura Rd #250, Agoura Hills, CA 91301, USA.
Is Earlydiagnostics Inc. registered in SAM.gov?
Yes. Earlydiagnostics Inc.'s SAM.gov registration is active through June 4, 2027.
What is Earlydiagnostics Inc.'s most recent federal award?
Earlydiagnostics Inc.'s most recent federal contract award is Topic 428 - NCI sbir transition to phase II solicitation FY 2023 (75N91023C00022), from National Cancer Institute, on August 15, 2023.
On GovTribe
See Earlydiagnostics Inc.'s full federal record
- Federal contract awards
- Federal grant awards
- Funding analysis by agency, NAICS and set-aside
- Similar vendors